OPAL-A is derived from the fruit of the Carica papaya (pawpaw) plant.
Pawpaw has been used widely in wound care for many years. OPAL-A is a proprietary filtrate produced through homogenisation, heat treatment, alkalisation and filtration of the pulp of ripened C. Papaya (the OPAL process).
OPAL-A is applied to wounds as a topical cream. It offers potential benefit in wound debridement (removal of necrotic tissue) and in the treatment of hard-to-heal wounds, including pressure ulcers, venous ulcers, diabetic foot ulcers and burns.
Preclinical studies and clinical evidence suggest that OPAL-A facilitates enzymatic debridement, wound closure and has anti-microbial effects in the treatment of such chronic wounds. A family of cysteine proteases are one of several active ingredients in OPAL-A. These enzymes are well known for their proteolytic activity, that is their ability to break down proteins into smaller molecules.
Our scientific research has focused in part on the role and mechanism of action of this family of active cysteine proteases identified in OPAL-A.
To date, OPAL-A has been successfully investigated in hundreds of patients, with over 40 case reports fully documented, suffering from various hard-to heal wounds and skin disorders. OPAL-A has proven effective in treating all patients, some of whom achieved complete wound closure.
Proteolytics’ commercial strategy for OPAL-A, includes expanding its use via Authorised Prescribers in Australia, Special Access Schemes and Compassionate Use.